Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?
Medical Oncology, University Campus Bio-Medico,Via Emilio Longoni, 83 00155 Rome, Italy. d.santini@ unicampus.it.
Daniele
D
Santini
Bruno
B
Vincenzi
Giuseppe
G
Tonini